These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18066142)

  • 61. A strategy for controlling potential interactions between natural health products and chemotherapy: a review in pediatric oncology.
    Seely D; Stempak D; Baruchel S
    J Pediatr Hematol Oncol; 2007 Jan; 29(1):32-47. PubMed ID: 17230065
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
    Ball R
    Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adverse reaction reports may be vulnerable to manipulation.
    Gibson L
    BMJ; 2005 Jun; 330(7503):1287. PubMed ID: 15933346
    [No Abstract]   [Full Text] [Related]  

  • 64. The use of natural health products by paediatric patients in respite care.
    Beringer A; Vaillancourt R; Villarreal G; Vadeboncoeur C
    Paediatr Child Health; 2015; 20(1):23-9. PubMed ID: 25722640
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pediatric natural health products recommended by chiropractic and naturopathic doctors in Canada.
    Porcino AJ; Solomonian L; Zylich S; Doucet C; Gluvic B; Vohra S
    Complement Ther Med; 2019 Apr; 43():196-200. PubMed ID: 30935530
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications.
    Haque A; Daniel S; Maxwell T; Boerstoel M
    Clin Ther; 2017 Apr; 39(4):675-685. PubMed ID: 28392076
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.
    Kay J; Feagan BG; Guirguis MS; Keystone EC; Klein AV; Lubiniecki AS; Mould DR; Nyarko KA; Ridgway AA; Trudeau ME; Wang J
    Biologicals; 2012 Nov; 40(6):517-27. PubMed ID: 23084808
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epidemiology of NHP-drug interactions: identification and evaluation.
    Brulotte J; Vohra S
    Curr Drug Metab; 2008 Dec; 9(10):1049-54. PubMed ID: 19075621
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Empowering consumers as contributors for health product safety: lessons from the Philippines.
    Hartigan-Go K
    Drug Saf; 2015 Apr; 38(4):329-35. PubMed ID: 25698347
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Study of Natural Products Adverse Reactions (SONAR) in Adults with Mental Health Conditions: A Cross-Sectional Study.
    Zorzela L; Khamba B; Sparks E; Necyk C; Urichuk L; Katzman MA; Koczerginski D; Chue P; Barnes J; Vohra S
    Drug Saf; 2021 Sep; 44(9):999-1006. PubMed ID: 34322863
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Regulatory issues related to functional foods and natural health products in Canada: possible implications for manufacturers of conjugated linoleic acid.
    Fitzpatrick KC
    Am J Clin Nutr; 2004 Jun; 79(6 Suppl):1217S-1220S. PubMed ID: 15159260
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Comparative Study of Medical Device Regulations:: US, Europe, Canada, and Taiwan.
    Chen YJ; Chiou CM; Huang YW; Tu PW; Lee YC; Chien CH
    Ther Innov Regul Sci; 2018 Jan; 52(1):62-69. PubMed ID: 29714608
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Channeling postmarketing patient data into pharmaceutical regulatory systems.
    Barbosa MD; Smith DD
    Drug Discov Today; 2014 Dec; 19(12):1897-912. PubMed ID: 25086288
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potential interactions between pharmaceuticals and natural health products in Canada.
    Singh SR; Levine MA
    J Clin Pharmacol; 2007 Feb; 47(2):249-58. PubMed ID: 17244776
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Study of natural product adverse events in adult HIV-infected patients in Canada.
    Sparks E; Zorzela L; Necyk C; Hughes C; Vohra S
    HIV Med; 2022 Jan; 23(1):29-38. PubMed ID: 34432937
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada.
    Raj N; Fernandes S; Charyulu NR; Dubey A; G S R; Hebbar S
    Ther Adv Drug Saf; 2019; 10():2042098619865413. PubMed ID: 31384423
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Australian and New Zealand governments agree to proceed with the joint regulatory agency for therapeutic products.
    Moore J
    J Law Med; 2011 Dec; 19(2):272-4. PubMed ID: 22320002
    [No Abstract]   [Full Text] [Related]  

  • 78. MotherNature: establishing a Canadian research network for natural health products (NHPs) during pregnancy and lactation.
    Koren G; Dugoua JJ; Magee L; Vohra S; Matsui D; Bérard A; Johnson B; Moretti M; Einarson A
    J Altern Complement Med; 2008 May; 14(4):369-72. PubMed ID: 18466066
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Use, clinical testing and safety of medical products and the reporting of incidents from the physicians's viewpoint].
    Ininger G; Kaiser RH
    Radiologe; 2003 Jan; 43(1):84-94; quiz 94-5. PubMed ID: 12645502
    [No Abstract]   [Full Text] [Related]  

  • 80. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.